Related Experiment Video
Updated: May 19, 2026

Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles
Published on: January 7, 2019
Mechanism of freeze-drying drug nanosuspensions
Nae-Oh Chung1, Min Kyung Lee, Jonghwi Lee
1Department of Chemical Engineering and Materials Science, Chung-Ang University, 221, Heukseok-dong, Dongjak-gu, Seoul, 156-756, Republic of Korea.
Abstract:
Drug nanoparticles prepared in a liquid medium are commonly freeze-dried for the preparation of an oral dosage in solid dosage form. The freezing rate is known to be a critical parameter for redispersible nanoformulations. However, there has been controversy as to whether a fast or slow freezing rate prevents irreversible aggregation. A systematic investigation is presented herein regarding the effect of both the molecular weight of the cryoprotectant and the freezing rate in order to elucidate the mechanism underlying irreversible aggregation. It was found that irreversible aggregation occurred during drying rather than freezing, although a proper freezing rate is critical. A more homogeneous distribution of the cryoprotectant and drug nanoparticles led to more redispersible powders. Thus, keeping the local concentration distribution of the nanoparticles and cryoprotectant fixed during the freezing step plays a critical role in how the freezing rate affects the redispersibility. The kinetic approach of excluding the tendency of ice crystal growth permitted an explanation of the controversial results. This study will facilitate an in-depth understanding of the aggregation process of nanoparticles or proteins during freeze-drying.
Related Concept Videos
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Colloidal precipitates
In Vitro Drug Dissolution: Alternative Methods
Theories of Dissolution: The Danckwerts' Model and Interfacial Barrier Model
In Vitro Drug Dissolution: Compendial Testing Models II

